Head & Neck

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

Despite the past decade of transformative advances in immuno-oncology, the response rate to checkpoint inhibitors (ICIs) remains low (~15%). There is significant interest in developing strategies to overcome resistance to these treatments, thus increasing response rate. Emerging evidence suggests that radiation therapy (RT) could potentially augment the antitumor response to ICIs through synergic effect. […]

Continuer la lecture…

2020 – ASCO – NBTXR3 Dose Expansion for Locally Advanced HNSCC

The standard of care non-surgical approach for locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients (pts) is concurrent chemoradiation with high dose cisplatin or cetuximab in case of contra-indication. Older age is a contra-indication to cisplatin, and cetuximab might not improve survival in older pts. It is therefore urgently needed to develop new treatment options for elderly pts with LA HNSCC. NBTXR3 are hafnium oxide nanoparticles that can enhance the efficacy of radiotherapy (RT) by increasing locally the deposited dose. […]

Continuer la lecture…

2020 – MHNCS – NBTXR3 for locally advanced HNSCC

Elderly and/or frail patients (pts) with head and neck squamous cell carcinoma (HSNCC) remain a challenging to manage and neglected population regarding clinical trials and data generation to support treatment choices. Despite representing 20% of the HNSCC population no consensus exists on what is the optimal treatment for these pts with locally advanced (LA) disease, vulnerable to treatment-induced toxicities with the current standard of care. […]

Continuer la lecture…

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continuer la lecture…

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

At the 2017 THNO in Nice, France, prof. C. Le Tourneau presented preliminary results of NBTXR3 in patients suffering from HNSCC. The treatment was associated with a positive safety profile, and preliminary effiacy evaluation, the local Complete Response rate is 83 % (dose level15% and 22%), with a duration of response of 22 months. […]

Continuer la lecture…

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

Hafnium oxide nanoparticles: an emergent promising treatment for solid tumors To improve tumor response, radiotherapy (RT) has been combined with chemical agents, radiosensitizers and monoclonal antibodies. However, the complexity of these associations in terms of pharmacology, local control, clinical outcome benefits or patient quality of life underlines the need for the development of new therapeutic approaches. […]

Continuer la lecture…

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

Continuer la lecture…

2017 – Abstract SITC Conference Maryland – Non Clinical

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

Continuer la lecture…

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer